Caribou Biosciences has received Fast Track designations from the FDA for its CB-010 and CB-012 therapies, aimed at treating refractory systemic lupus erythematosus (SLE) and relapsed or refractory acute myeloid leukemia (r/r AML) respectively. These designations are intended to expedite the development and review processes for these promising treatments.
AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.